Avicanna Inc.

Equities

AVCN

CA05368K1003

Biotechnology & Medical Research

Delayed Toronto S.E. Other stock markets 02:41:23 2024-05-16 pm EDT			5-day change	1st Jan Change
0.33 ^CAD	-9.59%		+3.17%	-7.14%

May. 14	Avicanna Up 4.5% as it Books Record Q1 Revenue, First Adjusted EBITDA Positive Quarter in Company History	MT
May. 14	Avicanna Books Record Q1 Revenue, First Adjusted Ebitda Positive Quarter in Company History	MT

Avicanna Inc. Announces Resignation of Setu Purohit as Chief Legal Officer

November 05, 2021 at 07:19 pm EDT

Avicanna Inc. announced that, with immediate effect, Setu Purohit will no longer serve as Chief Legal Officer of the Company. He will remain a member of the Company?s board of directors. The Company continues to execute on its transitional plans as it evolves from a pre-revenue R&D stage company into a rapidly expanding bio-pharmaceutical company with global operations and sales.

Latest news about Avicanna Inc.

Avicanna Up 4.5% as it Books Record Q1 Revenue, First Adjusted EBITDA Positive Quarter in Company History	May. 14	MT
Avicanna Books Record Q1 Revenue, First Adjusted Ebitda Positive Quarter in Company History	May. 14	MT
Avicanna Brief: Record Q1 revenue of $6.45 million representing a year-over-year increase of 451% compared to Q1 2023	May. 14	MT
Avicanna Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 13	CI
Avicanna Announced Results of Study in Patients with Epidermolysis Bullosa	May. 13	MT
Avicanna Brief: Announcing Results of Study in Patients with Epidermolysis Bullosa	May. 13	MT
Avicanna Raises About $2.1 Million in Non-brokered Private Placement	Apr. 19	MT
Avicanna Inc. announced that it has received CAD 2.125584 million in funding	Apr. 17	CI
Avicanna Inc. Announces Completion of Topical Gel Observational Real-World Evidence Study	Apr. 10	CI
Transcript : Avicanna Inc., 2023 Earnings Call, Apr 02, 2024	Apr. 02
Avicanna's Q4 Loss Narrows, Revenue Grows	Apr. 02	MT
Avicanna Brief: Reporting $16.8 Million in 2023 Revenue, representing an increase of 314% from 2022	Apr. 02	MT
Avicanna Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
Avicanna Announced Canadian Launch of 10% CBD (THC Free) Proprietary Formulation	Mar. 27	MT
Avicanna Brief: Announcing Canadian Launch of 10% CBD (THC Free) Proprietary Formulation	Mar. 27	MT
Avicanna Inc Announces the Canadian Launch of 10% CBD (THC Free) Proprietary Formulation	Mar. 27	CI
ThreeD Capital Inc. Announces New YouTube Channel	Mar. 25	MT
Avicanna Reports New Research Collaboration With Multi-national European-based Pharmaceutical Firm; Down 5.6%	Feb. 15	MT
Avicanna Reports New Research Collaboration With Multi-national European-based Pharmaceutical Firm	Feb. 15	MT
Avicanna Brief: Announcing New Research Collaboration with a Multi-national European-based Pharmaceutical Company	Feb. 15	MT
Avicanna Inc. Announces New Research Collaboration with a Multi-National European-Based Pharmaceutical Company	Feb. 15	CI
Avicanna Brief: Adds Approval issued by the Health Authority of Colombia INVIMA for Adjuvant treatment for seizures associated with Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS)	Feb. 13	MT
Avicanna Brief: Says Obtained Its First Indication-Specific Drug Registration with Trunerox	Feb. 13	MT
Avicanna Inc. Obtains Its First Indication-Specific Drug Registration with Trunerox	Feb. 13	CI
Avicanna Signs Supply, Licensing Pact With Multinational Pharmaceutical Firm	Feb. 05	MT

Chart Avicanna Inc.

Duration

Period

More charts

Company Profile

Avicanna Inc. is a Canada-based commercial-stage international biopharmaceutical company. The Company's scientific platform commercializes over thirty products across various market segments: Medical Cannabis & Wellness Products (RHO Phyto), Pharmaceutical Pipeline and Medical Cannabis Care Platform (MyMedi.ca). RHO Phyto formulary offers a diverse range of proprietary formulations, including oral, sublingual, topical and transdermal delivery. It has developed a pipeline of patent-pending drug candidates that are indication specific and in various stages of clinical development and commercialization. These cannabinoid-based drug candidates look to address unmet medical needs in the areas of dermatology, chronic pain and various neurological disorders. Its first pharmaceutical preparation (Trunerox) is in the drug registration stage in South America. MyMedi.ca is a medical cannabis care platform that serves medical cannabis patientsâ needs and enhances the patient's journey.

Sector

Biotechnology & Medical Research

Calendar

2024-08-11 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
AVICANNA INC.	-7.14%	26.19M
MODERNA, INC.	+33.28%	49.46B
IQVIA HOLDINGS INC.	+1.78%	42.58B
LONZA GROUP AG	+49.11%	42.49B
CELLTRION, INC.	-4.22%	29.09B
ICON PUBLIC LIMITED COMPANY	+11.53%	26.61B
ALNYLAM PHARMACEUTICALS, INC.	-22.66%	18.64B
BIO-TECHNE CORPORATION	+7.98%	13.16B
MEDPACE HOLDINGS, INC.	+29.60%	12.55B
UNITED THERAPEUTICS CORPORATION	+24.25%	12.1B

Other Biotechnology & Medical Research